vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1166Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРОЛЬ МАТРИКСНЫХ МЕТАЛЛОПРОТЕИНАЗ В ПРОЦЕССАХ РЕМОДЕЛИРОВАНИЯ СЕРДЦА У ДЕТЕЙ С РЕСТРИКТИВНОЙ КАРДИОМИОПАТИЕЙTHE ROLE OF MATRIX METALLOPROTEINASES IN PROCESSES OF HEART RE-MODELING IN CHILDREN WITH RESTRICTIVE CARDIOMYOPATHYБершоваТ.В.BershovaT.V.ГасановА.Г.GasanovA.G.ИвановА.П.IvanovA.P.БасаргинаЕ.Н.BasarginaE.V.БакановМ.И.BakanovM.I.ЗурабоваР.Б.ZurabovaR.B.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian Federation20092309201585Вопросы современной педиатрии3639Copyright © Бершова Т., Гасанов А., Иванов А., Басаргина Е., Баканов М., Зурабова Р., 20092009Бершова Т., Гасанов А., Иванов А., Басаргина Е., Баканов М., Зурабова Р.Bershova T., Gasanov A., Ivanov A., Basargina E., Bakanov M., Zurabova R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1166ReferencesSivasankaran S. Restrictive cardiomyopathy in India: the story of a vanishing mystery. J. Heart. 2009; 95 (1): 9–14.Sivasankaran S. Restrictive cardiomyopathy in India: the story of a vanishing mystery. J. Heart. 2009; 95 (1): 9–14.Salemi V., Leite J., Picard M. et al. Echocardiographic predictors of functional capacity in endomyocardial fibrosis patients. Eur. J. Echocardiogr. 2009; 10: 400–405.Salemi V., Leite J., Picard M. et al. Echocardiographic predictors of functional capacity in endomyocardial fibrosis patients. Eur. J. Echocardiogr. 2009; 10: 400–405.Pinto J., Parvatiyar M., Jones M. Troponin T mutation that causes infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development and impairs the inhibitory properties of troponin. J. Biol. Chem. 2008; 283 (4): 2156–2166.Pinto J., Parvatiyar M., Jones M. Troponin T mutation that causes infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development and impairs the inhibitory properties of troponin. J. Biol. Chem. 2008; 283 (4): 2156–2166.Kaski J., Syrris P., Burch M. et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. J. Heart. 2008; 94 (11): 1478 – 1484.Kaski J., Syrris P., Burch M. et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. J. Heart. 2008; 94 (11): 1478 – 1484.Hosenpud J., Nites N. Clinical, hemodynamic and endomyocardial biopsy findings in idiopathic restrictive cardiomyopathy. West. J. Med. 1986; 44 (3): 303 – 306.Hosenpud J., Nites N. Clinical, hemodynamic and endomyocardial biopsy findings in idiopathic restrictive cardiomyopathy. West. J. Med. 1986; 44 (3): 303 – 306.Hsu D., Pearson G. Heart failure in children: history, etiology, and pathophysiology. Circ. Heart. Fail. 2009; 2: 63–70.Hsu D., Pearson G. Heart failure in children: history, etiology, and pathophysiology. Circ. Heart. Fail. 2009; 2: 63–70.Gonzalez A., Lopez B., Ravassa S. et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc. Res. 2009; 81 (3): 509–518.Gonzalez A., Lopez B., Ravassa S. et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc. Res. 2009; 81 (3): 509–518.Martos R., Baugh J., Ledwidge M. et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur. J. Heart. Fail. 2009; 11 (2): 191–197.Martos R., Baugh J., Ledwidge M. et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur. J. Heart. Fail. 2009; 11 (2): 191–197.Иванов А.П., Исаев И.И. Эхокардиографические параметры здоровых детей дошкольного и школьного возраста. Педиатрия. 1987; 12: 17–20.Иванов А.П., Исаев И.И. Эхокардиографические параметры здоровых детей дошкольного и школьного возраста. Педиатрия. 1987; 12: 17–20.Басаргина Е.Н. Кардиомиопатии у детей, сопровождающиеся синдромом хронической сердечной недостаточности. Автореф. дис. … докт. мед. наук. М. 2003. 46 с.Басаргина Е.Н. Кардиомиопатии у детей, сопровождающиеся синдромом хронической сердечной недостаточности. Автореф. дис. … докт. мед. наук. М. 2003. 46 с.Hayashi T., Shimomura H., Terasaki F. et al. Collagen subtypes and matrix metalloproteinase in idiopathic restrictive cardiomyopathy. Int. J. Cardiol. 1998; 64 (2): 109–116.Hayashi T., Shimomura H., Terasaki F. et al. Collagen subtypes and matrix metalloproteinase in idiopathic restrictive cardiomyopathy. Int. J. Cardiol. 1998; 64 (2): 109–116.Bigg H., Rowan A., Barker M. et al. Activity of matrix metalloproteinase-9 against native collagen types I and III. J. FEBS 2007; 274 (5): 1246–1255.Bigg H., Rowan A., Barker M. et al. Activity of matrix metalloproteinase-9 against native collagen types I and III. J. FEBS 2007; 274 (5): 1246–1255.Rouet-Benzineb P., Buhler J., Dreyfus P. et al. Altered balance between matrix gelatinases (MMP–2 and MMP–9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP–9 in myosin heavy chain degradation. Eur. J. Heart Fail. 1999; 1 (4): 337–352.Rouet-Benzineb P., Buhler J., Dreyfus P. et al. Altered balance between matrix gelatinases (MMP–2 and MMP–9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP–9 in myosin heavy chain degradation. Eur. J. Heart Fail. 1999; 1 (4): 337–352.Welsh P., Whincup P., Papacosta O. et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle aged men. Q.J.M. 2008; 101 (10): 785–791.Welsh P., Whincup P., Papacosta O. et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle aged men. Q.J.M. 2008; 101 (10): 785–791.Zhang W., Zhong M., Yang G. et al. Matrix metalloproteinase–9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin converting enzyme. Cardiovasc. Pathol. 2008; 17 (6): 399–409.Zhang W., Zhong M., Yang G. et al. Matrix metalloproteinase–9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin converting enzyme. Cardiovasc. Pathol. 2008; 17 (6): 399–409.Yasmin S., McEniery C., Wallace S. et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005; 25 (2): 372–378.Yasmin S., McEniery C., Wallace S. et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005; 25 (2): 372–378.Rude M., Duhaney T., Kuster G. et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005: 46 (3): 555–561.Rude M., Duhaney T., Kuster G. et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005: 46 (3): 555–561.Marcy T., Ripley T. Aldosterone antagonists in the treatment of heart failure. Am. J. Health Syst. Pharm. 2006; 63 (1): 49–58.Marcy T., Ripley T. Aldosterone antagonists in the treatment of heart failure. Am. J. Health Syst. Pharm. 2006; 63 (1): 49–58.Jeong Y., Chaupin D., Matsushita K. et al. Aldosterone activates endothelial exocytosis. PNAS. 2009; 106 (10): 3782–3787.Jeong Y., Chaupin D., Matsushita K. et al. Aldosterone activates endothelial exocytosis. PNAS. 2009; 106 (10): 3782–3787.
The authors declare that there are no conflicts of interest present.